These Innovative Health Techs Are Tackling The Multi-Billion Dollar ADD/ADHD Epidemic

Two pioneering companies, Eyecarrot Innovations Corp (OTC: EYCCF, TSX.V: EYC)
and Karolinska Development (ST:KDEV), have developed technologies that
combat the visual learning disabilities often disguised as ADD.

ADD has been called an epidemic — and it’s spreading fastest among toddlers. In fact, half the children taking Ritalin for ADD/ADHD aren’t even 6 years old yet.[i]

It’s a scary thought. Based on what comprehensive research reveals about genetics and the brain, ADD or ADHD should show up in less than 6% of children[ii].  Meaning that as many as 1.6 million U.S. children deemed to suffer ADD may likely be misdiagnosed. 1.6 million!

In many states, the numbers are off the charts: in Kentucky and North Carolina, 15% of children are supposedly affected.[iii] In the South, 30% of boys are diagnosed with ADD (a rate that exploded since 2003 when schools began to lose funding if too many students fell behind in testing—unless the failing students had a handicap like ADD.[iv]). While nationally, the CDC reports that 11% of school children have been diagnosed with ADD. Almost twice what “should” be found.

 

“Children with ADHD are often forthcoming, social and highly creative. If their energy can be chanelled in the right direction they can achieve a huge amount.”

–Lisa Thorell, Karolinska Institute

Only in a few states, such as California and Colorado, do the statistics match the evidence.

That’s where companies like Eyecarrot Innovations (OTC: EYCCF, TSX.V: EYC) and Karolinska Development (ST:KDEV) come in.

Their groundbreaking therapies help reverse symptoms often mistaken for ADD/ADHD – and we believe tackling this high-profile issue will power their stock forward. 

Eyecarrot and Karolinska are perfectly poised to have a significant impact on the $12 billion ADD drug treatment market!

Why 1.6 Million Children Diagnosed With
ADD/ADHD Should Not Be Prescribed Medication

As Pulitzer- Prize-wining journalist Alan Schwartz puts it in his best seller ADHD Nation, “ADHD itself is not an epidemic—ADHD misdiagnosis is an epidemic.”

Schwartz goes on to say, “If the system functioned in such a way as to stay anywhere near the 5% diagnosis rate that the American Psychiatric Association’s official definition suggests, we wouldn’t be in this mess.”

Eyecarrot Innovations Corp and Karolinska intend to get children out of the mess. And they are succeeding because some of the misdiagnosed children have other cognitive problems, especially with memory. Even more of them actually have vision processing problems.

 

“Today, 1 in 4 people — that’s nearly 2 billion people worldwide— have visual performance issues that go beyond the ability to see clearly. Things like reading and learning challenges, poor athletic performance, and incomplete recovery from concussions or other traumatic brain injuries.”

—Adam Cegielski, Eyecarrot founder

Sweden’s prestigious Karolinska Development Institute (Stockholm: KDEE) promotes pharmaceutical research.

ADHD, Strokes, Aging, Brain Injuries…. Karolinska’s “Working”Answer Has Proven Results All Over the World

Karolinska’s Cogmed program to train working memory has been tested in 25 different studies since 2002. That was the year Dr. Torkel Klingberg assembled 14 children with ADD to see if training their working memory could help them. The idea behind that went back to studies dating from 1999, and Klibngsberg’s first test was so impressive the research has never stopped.

Karolinska now offers training in countries all over the world. As with the Eyecarrot program, Cogmed isn’t just for children with ADD or ADHD. It is helpful in recovery from strokes, concussions, and brain traumas because all those problems affect working memory.

In addition, because working memory peaks at age 25-30, Karolinska’s CogMed therapy is proving especially useful in older adults to improve clear thinking and organization.

In 2016, the journal, Psychology, concluded that  “Cogmed© WM training could be an effective training program for children with neurodevelopmental problems, with the best results for children with ADHD or learning problems.” That’s why this program could clearly answer the problem of overprescribing Ritalin, Adderall, and amphetimines for children with attention deficits.

The other pioneer in this cause is a young Canadian company, Eyecarrot Innovations Corp (OTC: EYCCF or TSX.V: EYC).  Its mission is vision-training systems to overcome learning, neurological and motor difficulties and is taking direct aim at helping the children who have been wrongly diagnosed because they have a condition that mimics ADD/ADHD.

The authoritative DSM-IV, Diagnostic and Statistical Manual of Mental Disorders has a checklist of 18 possible symptoms. A child has to show 6 or more of them. They have to be present for more than 6 months, and show up in at least two different environments. [v]

Unfortunately, 15 of those 18 traits also show up in children with vision-related learning disabilities!

For instance, children with “convergence insufficiency” are three times more likely to be diagnosed with ADD.  This is a very common condition where the eyes don’t continue to cooperate in tracking objects are they grow nearer.  With the right tests, it is easily diagnosed. It affects about 10% of children. So they hate to read. They talk when they should be listening. They do badly in school… and then someone says they have ADD.

Unfortunately a standard vision exam does not include those simple tests. Someone has to be alert to the potential problem. And then they can fix it. That’s where Eyecarrot Innovations helps.

Eyecarrot Innovations makes professional visual training programs for optometrists and eye care professionals to use in helping children, athletes, and adults overcome vision disabilities.

Convergence insufficiency is just one type. In total, up to 20% of children may be affected by some degree of a vision-related learning disorder that can be helped with guided therapy instead of drugs, operations, or glasses.

The Binovi Platform Tackles Learning Disabilities and Traumatic Brain Injuries With Continuous, High-Level, Neuro-Optic Training

Binovi is Eyecarrot Innovation’s professional grade tablet-based system for visual training and record keeping, and is distributed exclusively to eye-care professionals with advanced training in vision therapy.  The Binovi platform is unique in that it offers practitioners the hardware and software necessary to create customized strategies for treating patients with a wide variety of needs.

In addition to the vast ADD market, Eyecarrot Innovations’ Binovi program is a suite of more than 100 visual training exercises that help patients in at least seven different multi-billion dollar markets. For instance…

  • Convergence insufficiency—affects 2.5% to 13% of total population
  • Amblyopia—“lazy eye” where one eye does not coordinate with the brain affects 2-3% of the population
  • Strabismus—1.2 million surgeries a year, many that could be avoided with training instead
  • Athletes and active adults may also suffer from effects that follow concussions and traumatic brain injury—3 to 4 million people a year
  • Sports performance—is taking visual training seriously and the top five sports involve 75 million participants
  • Healthy Aging—eye changes affect 36 million drivers over 65
  • ADD/ADHD Misdiagnosis that could be corrected—1.6 million children

Eyecarrot Innovations’ Prestigious Heritage Is a Strong Marketing Advantage

Investors should think of Eyecarrot Innovations as a medical device stock, with all the phenomenal market-beating potential that class has shown in the past.

Eyecarrot Innovations has deep connections to the visual medical community. The system is based on the work of visionary medical device pioneer Mr. Harry Wayne, who invented the Wayne Saccadic Fixator (WSF).

Before his death at age 97, Wayne was known in the medical community for showing up at the annual meeting of the College of Optometrists in Vision Development, and revealing new inventions ranging from the WSF to the Perceptuomotor/Talking Pen, to the Directional Sequencer.

Eyecarrot Innovations purchased Wayne Engineering to bring Harry Wayne’s work forward.

In 2017, Eyecarrot Innovations began offering the Binovi training program to doctors and clinics, and is in the market to replace the 4,000+ Saccadic Fixators currently in use across the country.

Now is the time for investors to catch up, as sales should begin to explode in the coming year.

Eyecarrot Innovations Is A Boon to Vision Practices and Patients

Vision training… for ADD, concussions, aging eyes, sports performance… is a big business. Only some of the 146,000 optometry employees are trained to perform it, but we believe that number will rise as the income potential becomes obvious.

Eyecarrot Innovations’ Binovi makes it easy for developmental optometrists to plan a course of treatment, teach exercises, prescribe home drills, and monitor progress. This is a particularly attractive area for independent optometrists who are seeing glass and contact lens sales being lost to online competitors and large chains draw off their customers.

Visual training is a high-income practice. And we think thousands of optometrists will benefit from the ease and efficiency of Binovi to capture this important income stream:[vi]

  • Basic functional visual exam $220
  • Exam involving concussion or head trauma $350
  • Charge per visit for visual therapy $152
  • Charge for typical full course of treatment $1000 to $7000 per patient

This is medical practice independents can offer that the chains like Walmart will miss. This is why Mr. Harry Wayne and his successors at Eyecarrot Innovations’ strong ties to the medical community are so valuable to the future of EYCCF.

Now It’s About Leveraging Professionalism—6 Reasons Eyecarrot Innovations’ Binovi is Destined to Succeed

  1. It’s In the Doctors’ HandsThe Binovi program brings vision therapy home for millions of potential users, but this is serious training and it’s only available through doc
  2. Excellence Is a Requirement—Before using the system, doctors must apply and present credentials to prove there are trained vision therapists.
  3. This Software-Driven Tool Is a Medical Device—every year some medical device seems to top the charts for best investment of the year. Already this year, companies like Abiomed and Novocure are up more than 100%.
  4. Global Potential Is a Given. Eyecarrot Innovations treats visual challenges that affect children, accident victims, and athletes worldwide. It is already expanding to optometrists in Australia alongside Canada and the US.
  5. More than 100 Million Potential Users in the US Alone. Drivers over 65, athletes hoping to improve reactions and hand-eye coordination, children diagnosed with ADD (and adults!), patients with concussions or head traumas… visual training is a vital, widely needed service for them all.
  6. Joining The $308 Billion e-Health TrendThe greatest change in medicine now is the role that Internet-based medicine and information has carved out. The Binovi platform uses the best of information technology to deliver. And after 2 years of product development, EyeCarrot Innovations just signed multiple distribution deals to move their hardware into commercialization

Look First, Then Tell Your Broker You Have a Great Idea

You can find out everything you need to know about Eyecarrot Innovations Corp (TSX.V: EYC or OTC: EYCCF) at the company’s own website. You will see how the Binovi platform is used. Why patients do better with Binovi Coach in their hands than they do with traditional “home-alone” drills. Why doctors love it and see this as a way to expand and improve their practices.

And while you are at it, consider Karolinska (ST:KDEV), too. Karolinska is a large company conducting and financing high-level research in a number of problems beside ADD. This will not be a pure-play investment, but given the institute’s history of excellence the potential is high.

Eyecarrot Innovations and Binovi are alone out front. While visual drills are widely used, optometrists have been relying on show and tell—then sending patients home with handouts. We can add more about the hardware here, and how it gives practitioners data so we can measure performance changes over time.

Eyecarrot Innovations gives doctors a ready suite of exercises, a coaching system, tracking and reporting. All of which improve doctors’ professional impression on their patients and markedly upgrade their earning potential.

Take a look at their corporate presentation and watch the videos. Then tell your broker that you’ve found something special.

Available in the US on the OTC market, symbol EYCCF, and in Canada on the TSX, symbol EYC.

[i] https://latitudes.org/tag/ritalin/ according to CDC

[ii] https://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html

[iii] https://www.psychiatryadvisor.com/adhd/a-true-adhd-epidemic-or-an-epidemic-of-overdiagnosis/article/429034/

[iv] https://www.scientificamerican.com/article/big-pharma-s-manufactured-epidemic-the-misdiagnosis-of-adhd/

[v] http://www.minnesotavisiontherapy.com/adhd-add-vision

[vi] fees from

http://www.thevisiontherapycenter.com/costs-the-vision-therapy-center

 

The assembled information disseminated by Financials Trend is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Financials Trend does expect that investors will buy and sell securities based on information assembled and presented in Financials Trend. PLEASE always do your own due diligence, and consult your financial advisor.

All assembled information within Financials Trend is subject to change without notice. The assembled information within Financials Trend is based on information supplied by the company, press releases, SEC filings, or from other sources believed to be reliable as of the date of the report on the featured companies, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. An affiliate of the Financials Trend is a registered investment advisor. Financials Trend and its affiliates and authors are not, brokers, broker-dealers, market makers, investment bankers, analysts or underwriters.

Forward Looking Statements
Information in our emails and on Financials Trend will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. An example of forward-looking information are statements relating to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. These and similar forward statements are subject to a number of known and unknown risks and uncertainties outside our control that could cause actual operations or results to differ materially from those anticipated.

The cautionary statements made in this document should be read as being applicable to all related forward-looking statements wherever they appear on Financials Trend or in other communications.

We encourage you to visit the Securities Exchanges Commission Web site http://www.sec.gov and read about how to avoid Internet Scams and other valuable information.

Compensation
In order to be in full compliance with the Securities Act of 1933, Section 17(b), Financials Trend and its management will fully disclose if they receive fees from profiled companies or agents representing the profiled companies. These fees may be paid in cash, securities of profiled companies, or both, and will be completely disclosed in each profile.

Since Financials Trend receives compensation and its employees, affiliates, or members of their families could hold stock in the profiled companies, there is an inherent conflict of interest in the statements and opinions, and such statements and opinions are not independent.

Risks Involved
Financials Trend will not be responsible for or accept any liability for any losses arising from an investor’s reliance on or use of this assembled information. This assembled information is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. All assembled information provided is for informational purposes only and is not intended to be used as the sole source of information on a company.

Financials Trend disseminates information to those who wish to receive it. Small-cap and Penney stocks are considered to be highly speculative and may be unsuitable for all but very aggressive investors. Small-cap companies, micro-cap companies, penny stocks and/or thinly traded securities are inherently risky and volatile investments. You should be prepared to lose some or all of the money you invest. While historical data may be informative and positive, it should be understood there is no guarantee that past performance will be indicative of future results.

Buying and selling of shares
Financials Trend and its affiliates or officers could buy, hold, or sell shares, of mentioned Companies, in the open market without notice. Financials Trend and its affiliates will sell its shares in the event the shares rise in value, and in most cases will sell its shares for less than target prices. Financials Trend and its affiliates will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each person must make that decision based on their judgment.

PLEASE always do your own due diligence, and consult your financial advisor.

 

 

 

[1] https://latitudes.org/tag/ritalin/ according to CDC

[1] https://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html

[1] https://www.psychiatryadvisor.com/adhd/a-true-adhd-epidemic-or-an-epidemic-of-overdiagnosis/article/429034/

[1] https://www.scientificamerican.com/article/big-pharma-s-manufactured-epidemic-the-misdiagnosis-of-adhd/

[1] http://www.minnesotavisiontherapy.com/adhd-add-vision

[1] fees from

http://www.thevisiontherapycenter.com/costs-the-vision-therapy-center

 

The assembled information disseminated by Financials Trend is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Financials Trend does expect that investors will buy and sell securities based on information assembled and presented in Financials Trend. PLEASE always do your own due diligence, and consult your financial advisor.

All assembled information within Financials Trend is subject to change without notice. The assembled information within Financials Trend is based on information supplied by the company, press releases, SEC filings, or from other sources believed to be reliable as of the date of the report on the featured companies, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. An affiliate of the Financials Trend is a registered investment advisor. Financials Trend and its affiliates and authors are not, brokers, broker-dealers, market makers, investment bankers, analysts or underwriters.

Forward Looking Statements
Information in our emails and on Financials Trend will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. An example of forward-looking information are statements relating to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. These and similar forward statements are subject to a number of known and unknown risks and uncertainties outside our control that could cause actual operations or results to differ materially from those anticipated.

The cautionary statements made in this document should be read as being applicable to all related forward-looking statements wherever they appear on Financials Trend or in other communications.

We encourage you to visit the Securities Exchanges Commission Web site http://www.sec.gov and read about how to avoid Internet Scams and other valuable information.

Compensation
In order to be in full compliance with the Securities Act of 1933, Section 17(b), Financials Trend and its management will fully disclose if they receive fees from profiled companies or agents representing the profiled companies. These fees may be paid in cash, securities of profiled companies, or both, and will be completely disclosed in each profile.

Since Financials Trend receives compensation and its employees, affiliates, or members of their families could hold stock in the profiled companies, there is an inherent conflict of interest in the statements and opinions, and such statements and opinions are not independent.

Risks Involved
Financials Trend will not be responsible for or accept any liability for any losses arising from an investor’s reliance on or use of this assembled information. This assembled information is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. All assembled information provided is for informational purposes only and is not intended to be used as the sole source of information on a company.

Financials Trend disseminates information to those who wish to receive it. Small-cap and Penney stocks are considered to be highly speculative and may be unsuitable for all but very aggressive investors. Small-cap companies, micro-cap companies, penny stocks and/or thinly traded securities are inherently risky and volatile investments. You should be prepared to lose some or all of the money you invest. While historical data may be informative and positive, it should be understood there is no guarantee that past performance will be indicative of future results.

Buying and selling of shares
Financials Trend and its affiliates or officers could buy, hold, or sell shares, of mentioned Companies, in the open market without notice. Financials Trend and its affiliates will sell its shares in the event the shares rise in value, and in most cases will sell its shares for less than target prices. Financials Trend and its affiliates will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each person must make that decision based on their judgment.

PLEASE always do your own due diligence, and consult your financial advisor.

Leave a Response